Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Adaptive, Open-Label, Single Ascending Dose to Single-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-0184 in Participants With Chronic Heart Failure

NCT05659264 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT05659264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05659264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Adaptive, Open-Label, Single Ascending Dose to Single-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-0184 in Participants With Chronic Heart Failure
Lead sponsor
ModernaTX, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 5, 2022
Completion date
December 17, 2024
Enrollment
48 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

chronic heart failure